Favorable food stores and physical activity resources in neighborhoods were linked to ideal cardiovascular health.
The FDA has accepted for review its New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin]) injection.
WHO criteria better than National Osteoporosis Foundation criteria for identifying men who would benefit from drug treatment.
The FDA has found no clear evidence of increased cardiovascular risks associated with olmesartan medoxomil in patients with diabetes.
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
Many patients with adrenal incidentaloma may not receive the necessary care for their condition.
Please login or register first to view this content.